Search Results

Theralase® Technologies Inc. announced that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators at the Canadian Urological Association Bladder Cancer Forum and the American Urology Association, respectively.

Olympus will highlight a diverse urology portfolio that can help physicians treat bladder cancer, urinary stones and enlarged prostate during this year’s American Urological Association annual meeting May 3-6 in San Antonio.

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA ® Approval in Fireside Chat at the Annual Conference of the American Urological Association.

Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of multiple clinical studies at the 2024 American Urological Association Annual Meeting, which is being held in San Antonio, TX, from May 3 – 6, 2024.

UroGen Pharma Ltd. (Nasdaq: URGN) today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.

enGene Holdings Inc. (Nasdaq: ENGN) or (“enGene” or the “Company”) today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas.

EDAP TMS SA announced a recent presentation highlighting the positive, final results from a large, prospective, multicenter, non-inferiority study, the HIFI Study, comparing Focal One® high intensity focused ultrasound versus radical prostatectomy at the 119th American Urological Association Annual Meeting, which took place from May 3-6, 2024, in San Antonio, Texas, USA.